Clinical trials: Type 2 Diabetes Mellitus 1
Type 2 Diabetes Mellitus
A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus.
ORA-013-3 is a randomized, controlled study to test the efficacy and safety of an oral capsule of ORMD-0801 at several doses in patients with Type 2 Diabetes Mellitus (T2DM) who have not responded well to other glucose-lowering…
- Trial name
- NCT06731075
- Testing
- ORMD-0801 8 mg, ORMD-0801 16 mg
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Oramed, Ltd.
Diabete Type 1, Diabete Type 2
Effects of LP-LDL® on Lipid Metabolism, Glycemic Control, Inflammatory Markers, and Cognitive Function in Individuals With Prediabetes and Diabetes Mellitus
This randomized, double-blind, placebo-controlled clinical trial investigates the effects of the probiotic LP-LDL® (Lactobacillus plantarum ECGC 13110402) on lipid metabolism, glycemic control, inflammatory biomarkers, and…
- Conditions
- Diabete Type 1, Diabete Type 2, Prediabetes
- Trial name
- NCT07373392
- Testing
- Lactobacillus plantarum ECGC 13110402
- Where
- 2 sites in Denmark
- Volunteers
- 210 people
- Sponsor
- Aalborg University
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Evolution of Effectiveness of Diabetes Medical Care in Russia
The main aim of the present study is to evaluate the prevalence of individual microvascular and macrovascular complications among diabetes mellitus patients and to determine the percentage of diabetes mellitus patients achieved…
- Trial name
- NCT02574195
- Where
- Russia
- Volunteers
- 599 people
- Sponsor
- Endocrinology Research Centre, Moscow
Hypertension, Diabetes Type 2
Pharmacogenetics of Ace Inhibitor-Associated Angioedema
The investigators would like to find out if sitagliptin (dipeptidyl peptidase-4 or DPP4 inhibition), a drug to treat diabetes, affects blood vessel relaxation in healthy people receiving enalapril (angiotensin converting enzyme…
- Trial name
- NCT01413542
- Testing
- Sitagliptin (DPP4 inhibitor), Substance P,, bradykinin
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University
Diabetes Mellitus, Type 2
Trial to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of BI135585 XX Administered as Tablet and as Solution in Healthy Volunteers
The purpose of the study is to investigate the safety, tolerability, pharmacokinetics incl. dose proportionality, and pharmacodynamics of BI 135585 XX (Part 1), as well as the relative bioavailability of two different immediate…
- Trial name
- NCT01146886
- Testing
- BI 135585
- Where
- Germany
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus
Safety, Tolerability, Pharmacokinetics,Pharmacodynamics Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus
The purpose of this study is to investigate the safety and tolerability of repeated doses of HM11260C when given different regimens in subjects with type 2 diabetes mellitus (T2DM) on stable metformin monotherapy.
- Trial name
- NCT01452451
- Testing
- HM11260C
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
A Canadian Study of the Effectiveness of Tresiba® (Insulin Degludec) After Switching Basal Insulin in a Population With Type 1 or Type 2 Diabetes Mellitus
The purpose of this study is to collect historical data in real life conditions in a large group of people who have type 1 or type 2 diabetes and were treated with Tresiba® (insulin degludec) for at least 6 months.
- Trial name
- CAN-TREAT (NCT03674866)
- Testing
- Insulin degludec
- Where
- 32 sites in Canada
- Volunteers
- 662 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes Mellitus Maturity Onset
Smartguard Use in Real Life : a Longitudinal Study in Patients With Type 1 Diabetes
The reference treatment of the type 1 diabetes is intensified insulin therapy by insulin pump. The CGM (continuous glucose monitoring) is a technology available for a decade, which allows the continuous measure of interstitial…
- Trial name
- Smartguard (NCT03047486)
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Caen
Type 1 or 2 Diabetes
Diabetes and Psychological Profile
This study is based on the analysis of psychological and social questionnaires filled in by diabetic patients whose glycemic balance will be assessed by measuring blood levels of glycated haemoglobin.
- Trial name
- DPP (NCT01961466)
- Testing
- psychological and social self-administered questionnaires
- Where
- France
- Volunteers
- 592 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Type 2 Diabetes Mellitus, Coronary Artery Disease
Effects of Agonists of Glucagon Like Peptide - 1 Receptors (GLP-1R) on Arterial Stiffness, Endothelial Glycocalyx and Coronary Flow Reserve in Patients With Coronary Artery Disease and Patients With Diabetes Mellitus
Arterial stiffness is associated with increased risk for cardiovascular disease. Moreover, the integrity of endothelial glycocalyx plays a vital role in vascular permeability, inflammation and elasticity.
- Trial name
- NCT03010683
- Testing
- Liraglutide, Metformin
- Where
- Greece
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Athens
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
ACCU-CHEK® Aviva Expert Study: Does Use of a Bolus Advisor Improve Glycemic Control in Patients Not Achieving Optimal Control Using Multiple Daily Injections (MDI)?
This clinical, prospective, randomized, multi-center study determined if the use of an insulin bolus advisor improves glycemic control as measured by a change in HbA1c in patients failing multiple daily injection/intensified…
- Trial name
- ABACUS (NCT01460446)
- Testing
- Aviva Expert blood glucose meter, Aviva Nano blood glucose meter
- Where
- 33 sites in Germany, United Kingdom
- Volunteers
- 218 people
- Sponsor
- Hoffmann-La Roche
Ketosis Prone Diabetes
Modeling Ketosis-Prone Diabetes Remission Via Diverse Mechanisms of Glucotoxicity
The goal of this study is to quantify day-to-day changes in blood glucose during treatment towards remission in ketosis-prone diabetes (KPDM) and describe them using a mathematical model of KPDM pathogenesis and remission.
- Trial name
- NCT06699810
- Testing
- Continuous Glucose Monitoring, Insulin
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Emory University
Diabetes Mellitus
A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM12470
The purpose of this study is to investigate safety, tolerability, pharmacokinetics (PK) ad pharmacodynamics (PD) of HM12470 after single injection in T1DM and T2DM patients.
- Trial name
- NCT02302443
- Testing
- HM12470, Active comparator
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Type 2 Diabetes
Effect of Cycloset on Glycemic Control When Added to Glucagon-like Peptide 1 (GLP-1) Analogue Therapy
Purpose This study will examine the effect of the addition of Cycloset upon glucose metabolism (glycemic control including post prandial glucose metabolism) in individuals with inadequately controlled (HbA1c 7.5-10.0) type 2…
- Trial name
- NCT02299050
- Testing
- Cycloset
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Diabetes Mellitus, Type 2
A Single-dose Phase 1 Study of DBPR108 in Healthy Male Subjects
The study is being performed to assess the safety, tolerability, and pharmacokinetic (PK) and pharmacodynamic (PD) properties of single oral doses of DBPR108 in healthy male subjects.
- Trial name
- NCT01650324
- Testing
- DBPR108
- Where
- Taiwan
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- National Health Research Institutes, Taiwan
Diabetes Mellitus, Type 2
Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled, Study to Assess Safety, Tolerability, PK and PD Response of PB1023 Injection Following Single and Multiple SQ Doses in Adults With Type 2 Diabetes Mellitus
Primary objective: To evaluate the safety and tolerability of single and multiple ascending doses of PB1023 administered as a subcutaneous (SC) injection in adult subjects with T2DM. Secondary objectives: 1.
- Trial name
- NCT01236404
- Where
- 3 sites in United States
- Volunteers
- 80 people
- Sponsor
- PhaseBio Pharmaceuticals Inc.
Type 1 Diabetes, Type 2 Diabetes
Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder
The purpose of this study is to allow patients with specific needs for inhaled insulin to continue with inhaled insulin therapy using Technosphere Insulin after Exubera was withdrawn from the market.
- Trial name
- NCT01798914
- Testing
- Technosphere Insulin Inhalation Powder
- Where
- 14 sites in United States
- Sponsor
- Mannkind Corporation
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Gastric Pathophysiology in Diabetes
This is a comprehensive pathophysiological study assessing various gastric functions in patients with diabetes mellitus. The investigators aim to examine the stomach with various measurement devices to gain information about its…
- Conditions
- Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Functional Dyspepsia, Gastroparesis
- Trial name
- DiaFLIP (NCT06068114)
- Where
- 5 sites in Czechia, Slovakia
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Institute for Clinical and Experimental Medicine
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
The Role of Proper Insulin Injection Technique in the Treatment of Diabetes Mellitus
This is a prospective, post-marketing, single-arm clinical investigation on the effects of optimal insulin injection technique, in conjunction with the use of disposable Becton Dickinson (BD) Micro-Fine Plus 32G pen needles, by…
- Conditions
- Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Lipohypertrophy
- Trial name
- NCT04120974
- Testing
- Optimal insulin injection
- Where
- 4 sites in Russia
- Volunteers
- 90 people
- Sponsor
- Becton, Dickinson and Company
Diabetes Mellitus, Type 1
Evaluation of the Hypoglycaemia Notification Device Hyposafe H02
To evaluate the technical performance of the hyposafe H02 during everyday activities and during insulin-induced hypoglycaemia, in addition to safety issues associated with the implantation and use of the hyposafe H02 in subjects…
- Trial name
- NCT02925676
- Testing
- hyposafe H02
- Where
- 2 sites in Denmark
- Volunteers
- 8 people
- Sponsor
- UNEEG Medical A/S
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.